|
|
Article: M. D. Anderson Cancer Center to investigate Chemokine Therapeutics' lead chemokine antagonist in a preclinical study of human breast cancer.
- Article from:
- PR Newswire
- Article date:
- February 21, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TSX: CTI & OTCBB: CHKT
VANCOUVER, Feb. 21 /PRNewswire-FirstCall/ -- Chemokine Therapeutics Corp. (the Company) (OTCBB: CHKT; TSX: CTI), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, cardiovascular, and infectious diseases, today announced that it has entered into an agreement with The University of Texas M. D. Anderson Cancer Center of Houston, Texas to study the Company's lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist. Oncologists at M. D. Anderson Cancer Center will study the benefits of CTCE-9908 in studies investigating the drug's ability to inhibit the metastasis of a human breast cancer ...